Jeff Yass’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$48M Buy
88,579
+58,883
+198% +$33.2M ﹤0.01% 1543
2026
Q1
$17.6M Buy
29,696
+16,004
+117% +$7.97M ﹤0.01% 2387
2025
Q4
$6.67M Sell
13,692
-162,839
-92% -$75.8M ﹤0.01% 3596
2025
Q3
$74M Buy
176,531
+153,265
+659% +$51.5M 0.01% 1076
2025
Q2
$6.69M Buy
23,266
+16,625
+250% +$4.97M ﹤0.01% 3462
2025
Q1
$2.05M Sell
6,641
-139
-2% -$47.6K ﹤0.01% 5483
2024
Q4
$2.39M Sell
6,780
-12,656
-65% -$4.65M ﹤0.01% 4904
2024
Q3
$6.96M Buy
19,436
+3,028
+18% +$1.02M ﹤0.01% 3099
2024
Q2
$5.23M Sell
16,408
-18,273
-53% -$4.84M ﹤0.01% 3366
2024
Q1
$7.97M Buy
34,681
+13,242
+62% +$2.99M ﹤0.01% 2948
2023
Q4
$4.71M Sell
21,439
-42,100
-66% -$9.7M ﹤0.01% 3804
2023
Q3
$14.4M Buy
63,539
+5,686
+10% +$1.31M ﹤0.01% 2121
2023
Q2
$12.8M Sell
57,853
-29,731
-34% -$6.59M ﹤0.01% 2211
2023
Q1
$19.6M Buy
87,584
+61,403
+235% +$15.1M ﹤0.01% 1727
2022
Q4
$7.28M Sell
26,181
-7,417
-22% -$1.87M ﹤0.01% 2703
2022
Q3
$7.04M Buy
33,598
+31,889
+1,866% +$7.13M ﹤0.01% 2653
2022
Q2
$403K Sell
1,709
-6,006
-78% -$1.22M ﹤0.01% 8795
2022
Q1
$1.38M Sell
7,715
-2,573
-25% -$490K ﹤0.01% 6341
2021
Q4
$2.22M Sell
10,288
-38,963
-79% -$7.65M ﹤0.01% 5267
2021
Q3
$9.09M Buy
49,251
+42,419
+621% +$8.36M ﹤0.01% 3009
2021
Q2
$1.23M Sell
6,832
-26,952
-80% -$5.13M ﹤0.01% 7181
2021
Q1
$5.65M Buy
33,784
+8,875
+36% +$1.48M ﹤0.01% 3673
2020
Q4
$3.78M Buy
24,909
+15,992
+179% +$2.1M ﹤0.01% 3918
2020
Q3
$901K Buy
8,917
+2,057
+30% +$226K ﹤0.01% 6365
2020
Q2
$830K Sell
6,860
-8,108
-54% -$912K ﹤0.01% 6310
2020
Q1
$1.42M Sell
14,968
-10,234
-41% -$973K ﹤0.01% 4608
2019
Q4
$2.22M Sell
25,202
-42,516
-63% -$3.74M ﹤0.01% 4143
2019
Q3
$5.4M Buy
67,718
+19,931
+42% +$1.61M ﹤0.01% 2617
2019
Q2
$3.73M Buy
+47,787
New +$4.47M ﹤0.01% 3125
2018
Q1
Sell
-71,739
Closed -$9.11M 10235
2017
Q4
$10.6M Buy
+71,739
New +$9.12M ﹤0.01% 1776
2016
Q4
Sell
-2,679
Closed -$342K 10194
2016
Q3
$316K Buy
+2,679
New +$322K ﹤0.01% 6846
2016
Q2
Sell
-50,348
Closed -$5.62M 9374
2016
Q1
$5.61M Buy
+50,348
New +$6.37M ﹤0.01% 2155
2015
Q4
Sell
-46,731
Closed -$6.8M 10022
2015
Q3
$6.13M Buy
46,731
+41,931
+874% +$6.73M ﹤0.01% 2397
2015
Q2
$835K Sell
4,800
-111
-2% -$20K ﹤0.01% 6594
2015
Q1
$847K Sell
4,911
-47,465
-91% -$7.24M ﹤0.01% 6095
2014
Q4
$6.78M Buy
52,376
+41,391
+377% +$5.33M ﹤0.01% 2463
2014
Q3
$1.41M Sell
10,985
-62,589
-85% -$6.45M ﹤0.01% 5254
2014
Q2
$6.51M Sell
73,574
-83,071
-53% -$7.99M ﹤0.01% 2677
2014
Q1
$14.7M Sell
156,645
-26,529
-14% -$2.71M 0.01% 1574
2013
Q4
$20.7M Sell
183,174
-52,500
-22% -$4.73M 0.01% 1322
2013
Q3
$18.6M Buy
235,674
+4,532
+2% +$331K 0.01% 1271
2013
Q2
$15.2M Buy
+231,142
New +$14.9M 0.01% 1368

Other funds holding UTHR

Jeff Yass's UTHR Position: Q2 2026 in Review

Jeff Yass increased its United Therapeutics (UTHR) stake by 198% in Q2 2026, buying an estimated $33.2M and bringing the position to 88,579 shares worth $48M. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

Jeff Yass first reported a position in UTHR in Q2 2013 and has held it in 42 quarters since. The position peaked at $74M in Q3 2025. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Jeff Yass held 88,579 shares of United Therapeutics worth $48M as of Q2 2026.
  • Jeff Yass bought 58,883 United Therapeutics shares in Q2 2026, an estimated $33.2M.
  • United Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #1543 holding.
  • Jeff Yass first reported a position in United Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • Jeff Yass's United Therapeutics position peaked at $74M in Q3 2025.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.